|
|
Blood, 1 July 2007, Vol. 110, No. 1, pp. 37-44.
Prepublished online as a Blood First Edition Paper on March 15, 2007; DOI 10.1182/blood-2006-10-049072.
Previous Article | Table of Contents | Next Article 
CHEMOKINES, CYTOKINES, AND INTERLEUKINS
Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration
Paul Proost1,
Anneleen Mortier1,
Tamara Loos1,
Jo Vandercappellen1,
Mieke Gouwy1,
Isabelle Ronsse1,
Evemie Schutyser1,
Willy Put1,
Marc Parmentier2,
Sofie Struyf1, and
Jo Van Damme1
1 Laboratory of Molecular Immunology, Rega Institute, University of Leuven, Belgium;
2 Institut de Recherche Interdisciplinaire en Biologie humaine et moléculaire (IRIBHM), Université Libre de Bruxelles, Brussels, Belgium
CXCR3 ligands were secreted by tissue fibroblasts and peripheral bloodderived mononuclear leukocytes in response to interferon- (IFN- ) and Toll-like receptor (TLR) ligands. Subsequent purification and identification revealed the presence of truncated CXCL11 variants missing up to 6 amino acids. In combination with CD26/dipeptidyl peptidase IV, the metalloprotease aminopeptidase N (APN), identical to the myeloid cell marker CD13, rapidly processed CXCL11, but not CXCL8, to generate truncated CXCL11 forms. Truncated CXCL11 had reduced binding, signaling, and chemotactic properties for lymphocytes and CXCR3- or CXCR7-transfected cells. CD13/APN-truncated CXCL11 failed to induce an intracellular calcium increase but was still able to bind and desensitize CXCR3 for intact CXCL11 signaling. CXCL11 efficiently bound to CXCR7, but CXCL11 was not able to induce calcium signaling or ERK1/2 or Akt phosphorylation through CXCR7. CD26-truncated CXCL11 failed to attract lymphocytes but still inhibited microvascular endothelial cell (HMVEC) migration. However, further processing of CXCL11 by CD13 resulted in significant reduction of inhibition of HMVEC migration. Taken together, during inflammation or cancer, CXCL11 processing by CD13 may lead to a reduced number of tumor-infiltrating lymphocytes and in a more angiogenic environment.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Struyf, S. Noppen, T. Loos, A. Mortier, M. Gouwy, H. Verbeke, D. Huskens, S. Luangsay, M. Parmentier, K. Geboes, et al.
Citrullination of CXCL12 Differentially Reduces CXCR4 and CXCR7 Binding with Loss of Inflammatory and Anti-HIV-1 Activity via CXCR4
J. Immunol.,
January 1, 2009;
182(1):
666 - 674.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. H. Cox, R. A. Dean, C. R. Roberts, and C. M. Overall
Matrix Metalloproteinase Processing of CXCL11/I-TAC Results in Loss of Chemoattractant Activity and Altered Glycosaminoglycan Binding
J. Biol. Chem.,
July 11, 2008;
283(28):
19389 - 19399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Ji, C. M. Lee, L. W. Gonzales, Y. Yang, M. O. Aksoy, P. Wang, E. Brailoiu, N. Dun, M. T. Hurford, and S. G. Kelsen
Human type II pneumocyte chemotactic responses to CXCR3 activation are mediated by splice variant A
Am J Physiol Lung Cell Mol Physiol,
June 1, 2008;
294(6):
L1187 - L1196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Dohner
Implication of the Molecular Characterization of Acute Myeloid Leukemia
Hematology,
January 1, 2007;
2007(1):
412 - 419.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|